Inventor · disambiguated record
Yannis Morel
Also filed as: MOREL YANNIS
6 granted patents·7 pending applications·30 citations·filing 2009–2022
80Inventor score
Top patents by PatentIndex Score
13 records- 0188US9828427B2Anti-KIR3D antibodiesINNATE PHARMA·Filed 2015·Granted Nov 28, 2017·9 cites·7 claims
- 0283US9388246B2TLR3 binding agentsGAUTHIER LAURENT·Filed 2011·Granted Jul 12, 2016·9 cites·55 claims
- 0380US9181341B2Anti-KIR3D antibodiesANFOSSI NICOLAS·Filed 2010·Granted Nov 10, 2015·9 cites·11 claims
- 0473US8273541B2Compositions and methods for detecting TLR3CHEMIN KARINE·Filed 2009·Granted Sep 25, 2012·3 cites·14 claims
- 0560US2025002601A1Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2INNATE PHARMA·Filed 2022·Application pending·0 cites
- 0660US2024392008A1Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16aINNATE PHARMA·Filed 2022·Application pending·0 cites
- 0760US2024199750A1Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engagingINNATE PHARMA·Filed 2022·Application pending·0 cites
- 0853US2014234323A1Compositions and methods for detecting tlr3INNATE PHARMA·Filed 2014·Application pending·0 cites
- 0950US2011076296A1TLR3 Agonist CompositionsINNATE PHARMA SA·Filed 2009·Application pending·0 cites
- 1049US8715667B2Methods of treating patients having TLR3-positive cancerCHEMIN KARINE·Filed 2012·Granted May 6, 2014·0 cites·10 claims
- 1144US9944712B2TLR3 binding agentsINNATE PHARMA·Filed 2013·Granted Apr 17, 2018·0 cites·28 claims
- 1241US2016347853A1Tlr3 binding agentsINNATE PHARMA·Filed 2016·Application pending·0 cites
- 1337US2014065154A1Tlr3 binding agentsGAUTHIER LAURENT·Filed 2012·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →